Drug Profile

AIT 102

Alternative Names: AIT-102; EC-8042; Mithramycin-analogue - Quince Therapeutics

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EntreChem
Developer EntreChem; Quince Therapeutics
Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
Mechanism of Action Apoptosis stimulants; Sp1 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer; Ewing's sarcoma; Rhabdoid tumour

Most Recent Events

28 May 2026 No recent reports of development identified for preclinical development in Cancer in USA
18 May 2026 OrphAI Therapeutics has been acquired and merged into Quince Therapeutics
28 Jul 2025 No recent reports of development identified for preclinical development in Rhabdoid-tumour in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com